Business
Ovid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting
Emerging Science platform presentation highlights efficacy and safety data of OV101 in Angelman syndrome from the STARS study Research from Ovid's Fragile X
About this update from Ovid Therapeutics Inc.
[{"type":"text","content":"Emerging Science platform presentation highlights efficacy and safety data of OV101 in Angelman syndrome from the STARS study Research from Ovid's Fragile X program shows new insights for outcome assessmentsNEW YORK, April 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID) continues to build on its neuroscience research platform with the presentation of data from the OV101 (gaboxadol) investigational program for rare neurodevelopmental conditions. Ovid's presentations on Angelman syndrome and Fragile X syndrome are part of the program at the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia (May 4 - 10). The platform presentation and posters will highlight the data from OV101 in adolescents and adults with Angelman syndrome (STARS study) as well as frameworks to assess outcomes in Fragile X syndrome as a precursor to data that Ovid expects to announce in 2H 2019 (ROCKET study).\"Ovid's research efforts are focused on finding treatments for rare diseases, which are defined in the US as conditions affecting fewer than 200,000 people, and specifically, we seek to improve the lives of the approximately 8 million people in the US alone living with neurologic manifestations of rare diseases1,\" said Amit Rakhit, MD, MBA, Chief Medical Officer and Head of Research & Development at Ovid. \"The data we are presenting at AAN reflect the dedication of our R&D teams to investigate the use of OV101 as a potential treatment for Angelman syndrome and Fragile X syndrome, with each condition having high unmet medical need and no approved therapies.\"Ovid Therapeutics continues to expect the initiation of NEPTUNE, a global Phase 3 study of OV101 in children with Angelman syndrome in 2H 2019.Details of the presentations are listed below.Title: Methodology for Development of Indication-Specific Outcome Measures in Rare Disease Trials: An Innovative Research ApproachPoster ID: P1.9-073Poster Session 1: Research Methodology, Clinical Outcome and Quality ImprovementDate and Time: Sunday, May 5, 2019, 11:30 a.m. - 6:30 p.m. ETTitle: Development of a Conceptual Model to Inform a Clinical Outcome Assessment Strategy in Adolescents and Young Adults with Fragile X SyndromePoster ID: P1.9-067Poster Session 1: Research Methodology, Clinical Outcome and Quality ImprovementDate and Time: Sunday, May 5, 2019, 11:30 a....